Cognition Therapeutics Completes FDA Meeting for Zervimesine in Dementia with Lewy Bodies

Cognition Therapeutics completed a Type C meeting with the FDA to discuss plans for a Phase 2b study of zervimesine (CT1812) in dementia with Lewy bodies (DLB). The meeting aimed to review clinically meaningful endpoints for the study. The FDA and Cognition discussed plans for the study, and meeting minutes are expected later this quarter. The study will be conducted in mild-to-moderate DLB patients.